Table 2.
GA treatment reduces disease severity in EAEa
| Treatment | Incidence of EAE (%) |
Mean Day of Onsetb |
Mean cumulative Clinical Scorec |
Mean Maximum Severityd |
Mortality |
|---|---|---|---|---|---|
| EAE | 4/4 (100%) | 14.25 ± 1.26 | 37.63 ± 17.89 | 1.88 ± 0.75 | 0/4 (0%) |
|
EAE + GA
suppression |
1/4 (25%)* | 17.00 | 7.00 ± 14.00* | 2.00 | 0/4 (0%) |
|
EAE + GA
treatment |
4/4 (100%) | 14.25 ± 0.82 | 13.50 ± 13.80* | 1.75 ± 0.96 | 0/4 (0%) |
a
C57BL/6 mice were immunized with MOG35-55(200 μg)/CFA containing M. Tb (1mg/ml)/PT(400ng). Suppression: GA (1.2mg/day) i.p started together with disease induction (8 daily injections). Treatment: GA (1.2mg/day) i.p started after the appearance of clinical symptoms (8 daily injections). Mice (n=4 each group) were scored daily for 35 days, and the mean score of each group ±SD is shown.
b
Mean of the first sign of clinical scores for each animal.
c
Mean of the sum of scores for each animal over the entire observation period (35 days).
d
Mean of the highest clinical score exhibited by individual animals within a group during the entire course of EAE.
*
p< 0.05 by Anova.